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Focal adhesion kinase (FAK) regulates 
numerous cellular functions and is critical for 
processes ranging from embryo development to 
cancer progression. Although 
autophosphorylation on Tyr-397 appears 
required for FAK functions in vitro, its role in 
vivo has not been established. We addressed this 
question using a mutant mouse (fak∆) deleted of 
exon 15, which encodes Tyr-397. The resulting 
mutant protein FAK∆ is an active kinase 
expressed at normal levels. Our results 
demonstrate that the requirement for FAK 
autophosphorylation varies during development. 
FAK∆/∆ embryos developed normally up to E12.5, 
contrasting with the lethality at E8.5 of FAK-
null embryos. Thus, autophosphorylation on 
Tyr-397 is not required for FAK to achieve its 
functions until late mid-gestation. However, 
FAK∆/∆ embryos displayed hemorragies, oedema, 
delayed artery formation, vascular remodelling 
defects, multiple organs abnormalities, and 
overall developmental retardation at E13.5-14.5, 
and died thereafter demonstrating that FAK 
autophosphorylation is also necessary for 
normal development. Fibroblasts derived from 
mutant embryos had a normal stellate 
morphology and expression of focal adhesion 
proteins, Src family members, p53 and Pyk2. In 
contrast, in FAK∆/∆ fibroblasts and endothelial 
cells spreading and lamellipodia formation were 
altered with an increased size and number of 
focal adhesions, enriched in FAK∆. FAK 
mutation also decreased fibroblasts 
proliferation. These results show that the 
physiological functions of FAK in vivo are 
achieved through both autophosphorylation-
independent and autophosphorylation-
dependent mechanisms. 
 
 Focal adhesion kinase (FAK) is a non-receptor 
tyrosine kinase critical for processes ranging from 
embryo development (1) to cancer invasiveness and 
metastasis (2). FAK activation following integrin 
engagement or stimulation of a variety of 
transmembrane receptors, triggers its 
phosphorylation on tyrosine and the formation of 
multimolecular signaling complexes (3). FAK is 
enriched in focal adhesions, controlling their 
turnover and consequently adhesion-related 
processes such as spreading, migration, survival 
and proliferation (1). 
The important physiological role of FAK is 
demonstrated by the lethality of its null mutation at 
embryonic day (E) 8.5 (4, 5). Further studies using 
conditional deletion showed that FAK regulates the 
development of the nervous system (6-9), 
morphogenesis of the vascular network (5, 10, 11), 
and cardiac development (12-15). These reports 
clearly established that FAK is necessary for 
essential processes in vivo. 
In vitro studies have shown that, following its 
recruitment to focal adhesions, FAK 
autophosphorylation on Tyr-397 creates a high-
affinity binding site for multiple signaling proteins 
including the Src family kinases (SFKs) (3). 
Following their binding to phospho-Tyr-397 and 
activation, SFKs phosphorylate other FAK residues 
inducing its complete activation, its interaction with 
other signaling proteins and the stimulation of 
downstream signalling cascades (16). The FAK-
SFK complexes also regulate cytoskeleton 
rearrangement and downstream signaling pathways 
by phosphorylating partner proteins such as 
p130Cas and paxillin (17, 18). Thus FAK 
autophosphorylation on Tyr-397 appears to be 
critical for both FAK activation and scaffolding 
function in vitro, triggering the assembly of 
multimolecular complexes responsible for its 
cellular effects. Interestingly recent results showed 
that pharmacological inhibition of FAK activity and 
autophosphorylation did not block  tumor cells 
proliferation and apoptosis in vitro (19), suggesting 
that FAK may also have autophosphorylation-
FAK without autophosphorylation 
independent functions (20). Therefore it is 
particularly important to determine the role of Tyr-
397 in FAK functions in vivo. 
Here we addressed this question using a mutant 
mouse deleted of FAK exon 15, which encodes 19 
amino acids including Tyr-397 (21). Our results 
show that the requirement for FAK 
autophosphorylation varies during development and 
demonstrate that the physiological functions of 
FAK in vivo are achieved through both 
autophosphorylation-independent and 
autophosphorylation-dependent mechanisms. 
 
EXPERIMENTAL PROCEDURES 
Generation of FAK∆/∆ mice-FAK∆/∆ mice were 
generated (see also Supplemental Fig.1) in the 
course of experiments aiming at testing the role of 
FAK alternatively spliced exons (22). A DNA 
fragment containing exons 13-18 from the mouse 
Ptk2 gene was isolated from a SV129 genomic 
library (RPCI21MPAC, clone identification 
RPCIP711H19216Q2; RZPD, Berlin, Germany) 
and subcloned to construct the targeting vector 
(Supplemental Fig.1A). Embryonic stem (ES) cells 
isolated from male SV129 were electroporated with 
the targeting vector. Transfected cells were selected 
with hygromycin, 24 hours later and tested by PCR 
and Southern blotting (Supplemental Fig. 1A and 
B). For the present study we selected a clone which 
exhibited the homologous recombination event and 
an additional spontaneous deletion of a 307 bp 
genomic fragment including exon 15 (nt 34393031 
to 34393338 of FAK gene sequence NT_039621.7). 
This mutant allele of FAK gene was named FAK∆. 
C57BL/6 blastocysts were injected with FAK∆/+ ES 
cell and transferred to pseudo-pregnant mice. Male 
chimeric mice carrying the FAK∆ allele were mated 
to C57BL/6 female mice and offspring were 
genotyped based on their coat colour. 
Animal Care-FAK+/∆ mice were produced and 
maintained in the Fer-à-Moulin Institute animal 
house in stable conditions of temperature (22°C) 
and humidity (60%) with a constant cycle of 12h 
light and 12h dark and free access to food and 
water. All experiments were in accordance with the 
guidelines of the French Agriculture and Forestry 
Ministry for handling animals (decree 87849, 
license A 75-05-22).  
Genotyping by PCR-Mice and embryos were 
genotyped by PCR analysis (details in 
Supplemental Fig. 4) using DNA extracted from tail 
biopsies.  
Antibodies-Sources: pY-397-FAK, pY-418-Src and 
pY421-cortactin: Biosource Inc; pY-118-paxillin, 
pY-410-p130Cas, pY-576/577-FAK and pY-925-
FAK: Cell Signaling Inc; FAK (clone 4.47) and 
cortactin: Upstate Biotechnology Inc; Fyn (FYN3), 
Src (SRC2), FAK (C-20) and GAPDH: Santa-Cruz 
Biotechnology Inc; rat PECAM-1 monoclonal 
CD31 (clone MEC13.3), CD102, p130Cas, paxillin: 
Beckton Dickinson Biosciences; biotinylated TuJI: 
R&D systems; smooth muscle α-actin-FITC 
(mouse clone 1A4) and vinculin: Sigma-Aldrich 
Inc. Pyk2 rabbit antibody was produced in house. 
Rhodamin-conjugated phalloidin and all secondary 
antibodies (AlexaFluor) were from Molecular 
Probes, Invitrogen Inc, and Jackson Immune 
Research Laboratory.  
Whole mount staining-Embryos were fixed in 4% 
paraformaldehyde in PBS. After dehydratation in a 
series of methanol, they were treated with 1% H2O2, 
rehydrated from methanol to PBS, and blocked in 
4% (w/v) bovine serum albumin- 0.1% (v/v) Triton 
X-100. They were then incubated with anti-
PECAM-1 (1:500) in 4% BSA 0.1%Triton X-100 
in PBS at 4°C overnight followed by peroxydase-
conjugated secondary antibody. The reaction was 
developed in 0.03% 3-3'-diaminobenzidine with 
H2O2. For the whole-mount skin immunostaining, 
skins were removed after embryo fixation, 
permeabilized for 2 hours (0,2% triton  X100) and 
blocked (Roche, ref 11096176001) for 2 hours prior 
to incubation with antibodies against PECAM-1 
and biotinylated TuJI (1:200 dilution) in 0.1% triton 
+ 1% BSA+ 1% Goat serum overnight at 4°C. After 
washes for 4 hours, skins were incubated with 
secondary antibody (AlexaFluor 555 goat anti-rat) 
and monoclonal anti smooth muscle α-actin-FITC 
in blocking solution for 2 hours. Acquisitions were 
performed with a confocal microscope (Leica, SP5, 
10x magnification). 
Tissue extraction and preparation for 
immunoblotting-Tissues and organs from embryos 
or adult mice were frozen immediately after 
dissection and sonicated later in 100°C, 1% (w/v) 
SDS (1%) containing NaVO4 (1 mM), placed in a 
100°C heating block for 3 min and processed as 
described in the immunoblotting section. 
Cell culture-COS7 cells were grown and 
transfected with Lipofectamin 2000 (Invitrogen) as 
previously described (23). For the primary 
fibroblasts, four FAK+/+ and 3 FAK∆/∆ independent 
mouse embryonic fibroblasts (MEF) populations 
were prepared from 7 littermates E12.5 embryos of 
2 different litters obtained from heterozygous 
FAK without autophosphorylation 
crossings and cultured as described (24). All 
experiments were performed between passage 1 and 
3. The 7 MEF populations were tested separately in 
each experiment. Primary endothelial cells (EC) 
were isolated from FAK+/+ and FAK∆/∆ E12.5 and 
E13.5 embryos using magnetic beads (Dynabead 
M-450; Dynal Corp.) and rat anti-mouse PECAM-1 
(CD31) (5). For the fibronectin replating 
experiments, MEF or EC were prepared as 
described (25) before being plated on tissue culture 
dishes or glass coverslips precoated with polylysine 
(50 µg/ml) or fibronectin (10 µg/ml) and processed 
for immunoblotting or immunofluorescence at the 
indicated times.  
Immunoblotting-After the appropriate treatment, 
cells were rinsed, frozen on dry ice, lysed with 
boiling SDS (1%) containing NaVO4 (1 mM), 
sonicated and boiled for 3 min. Protein 
concentration was determined with the BCA assay 
(Pierce) and 50 to 100 µg of protein were analyzed 
by SDS-PAGE. Quantification of immunoblots was 
performed with Odyssey Li-Cor. Data were 
normalized to the mean value of untreated controls 
in the same autoradiograms. 
Immunofluorescence-Cells were fixed for 15 
minutes in 4% (w/v) PFA and permeabilized with 
TritonX100 0.05% for 5 min. After blocking and 
incubation with primary antibody overnight, cells 
were incubated with Alexa-488- or Cy3-coupled 
secondary antibodies or rhodamin-conjugated 
phalloidin (1/400) for 1 hour and mounted in 
Vectashield with DAPI. Acquisition of the images 
was performed on a Leica DM600B equipped with 
a numerical camera CCD Micromax (Princeton 
Instrument) at 20x (N.A. 0.7, PL APO) or 40x 
(N.A. 1.25, oil, PL APO) using Metamorph 
software. In experiments with EC, only cells 
positive for CD31 or CD102 were selected for 
analysis of immunofluorescence with antibodies 
recognizing other proteins. 
Proliferation studies-MEFs were plated separately 
in triplicate at 7500 cells/well in 24-well plates. The 
growing medium was changed every other day and 
cells were fixed everyday with cold methanol and 
kept at -20°C until the end of the experiment. At 
that time cells were stained with crystal violet 
staining and solubilized (24) and cell number was 
estimated with a spectrophotometer at 590 nm. Data 
points were the average of triplicates. 
 
RESULTS AND DISCUSSION 
Generation of fak∆  mice expressing an active but 
autophosphorylation-deficient mutant form of FAK-
Mutant mice (fak∆) were generated from ES cells in 
which FAK exon 15 (21) was deleted by 
homologous recombination (Supplemental Fig. 1, A 
and B). Analyses of tissues from heterozygous 
FAK+/∆ mice by RT-PCR (data not shown) and 
western blotting (Supplemental Fig. 1C), confirmed 
that the deletion of exon 15 did not alter FAK 
mRNA open reading frame, resulting in the 
expression of the expected full length mutant 
protein FAK∆ deleted of the 19 residues (including 
Tyr-397) coded by exon 15 and located between the 
N-terminal four-point-one, ezrin, radixin, moesin 
(FERM) and kinase domains (21) (Fig. 1A). FAK∆ 
was expressed at the same levels as normal FAK 
encoded by the wild type allele (Supplemental Fig. 
1C). As expected, FAK∆ was not detected by P-
Tyr-397-specific antibodies in transfection 
experiments. Using a transphosphorylation assay in 
COS7 cells (23), we found that the basal kinase 
activity of FAK∆, was moderately increased  
(Supplemental Fig. 2). Thus fak∆  mice constitute an 
interesting model to study the role of FAK 
autophosphorylation in vivo. 
FAK∆/∆ mice display multiple abnormalities after 
mid-gestation and lethality between E14.5 and 
E16.5-The intercrossing of FAK+/∆ mice produced 
only 0.25% FAK∆/∆ pups (Table 1) compared to the 
expected mendelian ratio of 25%. This result 
suggested that the dizygous expression of FAK∆ 
was lethal for the vast majority of FAK∆/∆ embryos. 
To define the stage at which the FAK∆/∆ embryos 
died and to compare their phenotype to FAK+/+ 
embryos, dated embryos were collected during 
development and genotyped by PCR. At E11.5 and 
E12.5, living FAK∆/∆ embryos were found at 
mendelian ratios (Table 1 and Fig. 1B). They were 
indistinguishable from their control littermates in 
morphology and development and showed normal 
vascularization by whole-mount anti-PECAM1 
immunostaining (Supplemental Fig. 3A and data 
not shown). At E13.5, FAK∆/∆ embryos were 
smaller than FAK+/+ embryos and showed abnormal 
superficial vasculature, hemorrhagic liver, multiple 
body hemorrhages and oedemas (Fig. 1C), 
indicating that FAK autophosphorylation was 
required for normal development after E12.5. A 
decrease in the ratios of living FAK∆/∆ embryos 
compared to wild type was observed between E13.5 
and E15.5 and very few survived past E16.5 (Table 
1 and Fig. 1B). FAK∆/∆ embryos also showed 
alteration and retardation in heart, lung, liver and 
limbs development at E14.5 (Fig. 1C) and yolk sac 
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vascularization defects were observed at E15.5 
(Supplemental Fig. 3B). Since vascular defects 
were observed in FAK∆/∆ embryos from E13.5, we 
further investigated vascular development by 
performing skin whole-mount immunofluorescence 
from E14.5 embryos. Smooth muscle actin staining 
was visible on arteries formed in the skin of wild 
type embryos, whereas FAK∆/∆ arteries only showed 
weak smooth muscle actin staining in the proximal 
part. In addition, there was a defect in the 
remodelling of the vascular plexus in FAK∆/∆ 
embryos (Fig. 1D). These results demonstrate that 
the homozygous FAK mutation deleting the 
autophosphorylation site, resulted in vascular 
defects and developmental retardation apparent at 
E13.5, and embryonic lethality between E14.5 and 
E16.5. Although the stage of embryonic lethality 
caused by the early conditional deletion of FAK in 
endothelial cells remains controversial (5, 10), one 
study reported lethality between E13.5 and E14.5 
with a phenotype very similar to what we observed 
in FAK∆/∆ embryos (5). Thus, it is likely that 
vascular abnormalities were an important factor in 
embryonic lethality, although we cannot exclude 
that failure of other organs also played a role. 
The mid-gestation lethality of FAK∆/∆ embryos 
contrasted with the early developmental lethality at 
E8.5 reported in FAK-null embryos (4, 26) even in 
the same genetic background as fak∆ mice (5). 
Comparison of the survival of FAK∆/∆ and FAK-/- 
embryos during development confirmed that the 
absence of FAK led to an earlier developmental 
lethality than the absence of FAK 
autophosphorylation (Fig. 1B). Thus, FAK 
requirement for normal development is independent 
of its autophosphorylation until E13.5. Moreover, 
we observed rare (0.25%) verified FAK∆/∆ mice, 
which survived to adulthood and were fertile (Table 
1 and Supplemental Fig. 4) whereas no FAK-null 
adult mice have been reported (4, 5, 26). This 
observation demonstrates that the absence of FAK 
autophosphorylation can be compensated in very 
rare cases in vivo.  
FAK∆/∆ mutation has minor effect on the levels of 
associated proteins-Next we monitored the 
expression of FAK∆ and FAK-associated proteins 
in mutant embryos. FAK∆ protein was expressed at 
the same level as FAK in FAK+/∆ embryos, or in 
FAK∆/∆ embryos compared to FAK+/+ embryos at 
every developmental stage tested, but, as expected, 
only FAK was phosphorylated on Tyr-397 (Fig. 2A 
and data not shown). Since the cytoskeleton 
rearrangements and downstream signaling 
pathways regulated by FAK are mediated by its 
interaction with SFKs and focal adhesions proteins 
such as paxillin and p130Cas (17, 18), we also 
monitored their expression. We found in E14.5 
mutant embryos, a moderate increase in the 
expression of paxillin and p130Cas, as well as 
cortactin (Fig. 2A) which facilitates cortical actin 
polymerization (27). In contrast, vinculin, another 
focal adhesion protein anchoring F-actin to the 
membrane, and Src and Fyn were expressed at the 
same levels in FAK+/+ and FAK∆/∆ embryos (Fig. 
2A). The FAK-related tyrosine kinase Pyk2 was 
barely detectable in both FAK+/+ and FAK∆/∆ 
embryos and no increase was observed in mutant 
mice at any developmental stage tested (data not 
shown). Interestingly, a very strong increased 
expression of Pyk2 and paxillin has been reported 
in some FAK-null tissues or cell types (11, 20, 25, 
28, 29) and Pyk2 overexpression can functionally 
compensate FAK absence (11, 25, 28, 29) and/or 
have unrelated deleterious consequences (28). 
Based on these results it has been proposed that 
FAK maintains a low level of Pyk2 expression in 
normal conditions in some tissues or cell types (11, 
28). The lack of Pyk2 upregulation in FAK∆/∆ 
embryos, suggests that FAK autophosphorylation is 
not required to maintain a low level of Pyk2 
expression during development in vivo. Our results 
also support the hypothesis that Pyk2 over-
expression might contribute to the severity of FAK-
null mutation (20, 28). 
In order to characterize the cellular consequences of 
the mutation on the regulation of associated 
proteins, we studied primary mouse embryonic 
fibroblasts (MEFs) from E12.5 FAK+/+ and FAK∆/∆ 
embryos. Western blotting experiments showed that 
FAK∆ was expressed at the same levels in FAK∆/∆ 
MEFs as FAK in FAK+/+ MEFs (Fig. 2B). Only a 
moderate increase (<2-fold) in the level of Pyk2 
was observed in these cells compared to FAK+/+ 
MEFs (Fig. 2B). This result contrasted with the 
strong overexpression of Pyk2 that we observed in 
FAK-/- fibroblasts (~10 fold, data not shown) and 
that had also been previously reported (25, 28, 29). 
The levels of vinculin, p130Cas, paxillin, cortactin, 
Fyn and Src, were not changed by the fak∆/∆ 
mutation in MEFs (Fig. 2B). Finally, similarly to 
FAK+/+ MEFs, no p53 was detected in FAK∆/∆ 
MEFs (Fig. 2C) in contrast to its strong expression 
in primary FAK-/- fibroblasts (20). Thus, FAK∆/∆ 
MEFs are an interesting model to study the effects 
of the FAK mutant lacking Tyr-397, in a context 
FAK without autophosphorylation 
where its functionally related proteins and partners 
are expressed at levels close to normal.  
Dramatic alteration of the phosphorylation 
response to cell adhesion in FAK∆/∆ MEFs- We 
tested the effects of integrin engagement on the 
phosphorylation of FAK tyrosine residues in 
FAK∆/∆ MEFs. As expected, plating wild-type 
MEFs on fibronectin (FN) induced the 
phosphorylation of wild type FAK on Tyr-397, Tyr-
576/577, which allows its full enzymatic activation, 
and on Tyr-925, which regulates the recruitment of 
partners and downstream signaling pathways, as 
well as FAK localization to focal adhesions (16, 30) 
(Fig. 3A and Fig. 3B). In contrast, the FN-induced 
phosphorylation of these residues was lost in 
FAK∆/∆ MEFs (Fig. 3A and Fig. 3B), although SFKs 
were similarly activated in wild type and mutant 
MEFs (data not shown). These results show that 
autophosphorylation on Tyr-397 is critical for SFK-
dependent tyrosine phosphorylation of FAK and 
confirm that the moderate increase of FAK∆ basal 
kinase activity (Supplemental Fig. 2) has no effect 
on FAK activation and Src-mediated signaling. We 
also examined p130Cas and paxillin, whose 
phosphorylation by the FAK-SFK complex is 
important for cytoskeleton rearrangement and 
activation of downstream signaling pathways (17). 
The phosphorylation of both proteins was 
stimulated by FN in FAK+/+ but not in FAK∆/∆ MEFs 
(Fig. 3C, D) despite a similar interaction of 
endogenous FAK and FAK∆ with both p130Cas 
and paxillin in these cells or after overexpression in 
COS7 (data not shown). In contrast, the 
phosphorylation of cortactin, which is known to be 
catalyzed by SFKs independently of FAK (27), was 
unaffected in FAK∆/∆ cells (Fig. 3E). Previous 
studies proposed that the phosphorylation of 
p130Cas and paxillin by Src may be achieved 
through both FAK-dependent and independent 
mechanisms (29, 31). However, the absence of any 
significant phosphorylation of p130Cas and paxillin 
in FAK∆/∆ cells plated on fibronectin suggests that 
FAK autophosphorylation is required for targeting 
SFKs to p130Cas and paxillin in response to 
integrin engagement. 
Spreading and morphology are altered in FAK∆/∆ 
fibroblasts and endothelial cells- Integrin 
engagement mediates the adhesion of many cell 
types and induces organized actin polymerization 
resulting in the extension of the membrane 
(lamellipodia) at the periphery of spreading cells. 
Since FAK plays a critical role in adhesion and 
spreading (4, 10, 28), we investigated the 
consequences of exon 15 deletion on these 
processes. After 30 min on polylysine (PL) or FN, 
FAK∆/∆ cells showed delayed spreading compared 
to FAK+/+ MEFs and lacked continuous smooth-
round peripheral membrane extensions, 
characteristic of lamellipodia (Fig. 4A). Instead, 
FAK∆/∆ cells exhibited multiple thinner membrane 
protrusions containing dense actin fibers (Fig. 4A). 
These narrow actin-rich membrane extensions of 
FAK∆/∆ MEFs remained prominent after 1 hour on 
FN and were identified as abnormal lamellipodia 
since cortactin, which normally localizes at the 
edges of protruding lamellipodia, was localized at 
their tips (Fig. 4B). A similar phenotype was 
reported in several cell types lacking FAK 
expression (10, 32, 33). Lamellipodia formation and 
cell spreading in response to integrin engagement 
has been reported to require the release by FAK of 
the Arp2/3 complex bound to its FERM domain, 
triggered by autophosphorylation of Tyr-397 (32). 
Thus, the defects observed in FAK∆/∆ cells may be 
due to the disruption of this mechanism. After 2 
hours on FN, immunostaining of both cell types for 
vinculin, a protein localized at focal adhesions, 
showed an increase in the number and size of focal 
adhesions in FAK∆/∆ MEFs compared to wild type 
cells (Fig. 4C). Both FAK+/+ and FAK∆/∆ MEFs 
acquired an apparent typical fibroblastic stellate 
morphology with radial actin stress fibers after 20 
hours on PL or FN (Fig. 4D). However, 
FAK∆/∆ MEFs lacked the large lamellipodia 
observed in wild type. Furthermore, they displayed 
a persistent increase in the number and size of focal 
adhesions localized at the tips of stress fibers, 
characterized by a stronger enrichment of FAK 
immunoreactivity than in FAK+/+ MEFs (Fig. 4D). 
Since FAK∆/∆ embryos showed important 
vascularization defects, we also monitored the 
properties of primary FAK∆/∆ endothelial cells (EC) 
in response to integrin engagement. After 2 hours 
on FN, abnormal lamellipodia and cell spreading 
defects were observed in mutant EC which showed 
enlarged focal adhesions enriched in FAK∆ (Fig. 
4E and F). Interestingly, a similar phenotype was 
reported in primary FAK-/- EC (10), which also 
showed no increased expression of Pyk2. The 
enrichment of FAK∆ compared to FAK at focal 
adhesions, was also observed following its 
expression by transfection in FAK-/- fibroblasts 
(data not shown) similarly to the mutant 
FAKY397F overexpressed in FAK-/- cells (29). 
Since the phosphorylation of Tyr-925 is important 
FAK without autophosphorylation 
for the release of FAK from focal adhesions and 
their turnover (30), the deficit in FAK Tyr-925 
phosphorylation that we observed in FAK∆/∆ cells 
(Fig. 3A and B) may contribute to the increased 
number and size, of focal adhesions, and their 
enrichment in FAK∆ protein (Fig. 4A-F). The 
stellate morphology of FAK∆/∆ MEFs contrasts with 
the ultraspread morphology of FAK-/- fibroblasts 
stably expressing FAKY397F in the same 
experimental conditions (29). The high expression 
of Pyk2 and FAKY397F in these cells may be 
responsible for their different phenotype compared 
to FAK∆/∆ MEFs that contain close to normal levels 
of Pyk2 and FAK∆. Our results also demonstrate 
that FAK∆/∆ cells have a delayed spreading 
characterized by disorganized lamellipodia, which 
never reach the same extent as in FAK+/+ MEFs, 
and an increased number and size of focal 
adhesions, enriched in FAK∆. These defects, also 
observed in the mutant endothelial cells, may 
underlie the vascular abnormalities observed in 
FAK∆/∆ embryos.  
Proliferation of FAK∆/∆  fibroblasts is decreased-
FAK is implicated in the control of cell growth (28, 
34), although its importance depends on cell types 
(19, 20, 35). We compared the proliferation of 
FAK+/+ and FAK∆/∆ MEFs in standard culture 
conditions (10 % serum). No differences in 
proliferation between wild type and mutant MEFs 
were observed during the first 3 days. Thereafter, 
FAK∆/∆ MEFs proliferated more slowly than FAK+/+ 
and they reached a lower saturation density (Fig. 
5A). These results demonstrate that FAK 
autophosphorylation on Tyr-397 is required for 
normal proliferation of MEFs (Fig. 5A). However, 
growth of FAK∆/∆ MEFs was mostly restored at a 
higher serum concentration (Fig. 5B), suggesting 
that the proliferative defect due to the lack of FAK 
autophosphorylation could be compensated by 
increased proliferative signals. FAK-/- embryonic 
mesodermal cells in vivo or FAK-/- fibroblasts in 
vitro also exhibited a proliferation defect attributed 
to an up-regulation of p53 (20, 36). This up-
regulation may account for the use of a p53-/- 
background to establish FAK-/- fibroblasts (4). 
Indeed FAK FERM domain binds to and causes the 
degradation of p53, independently of its 
autophosphorylation and kinase activity (20, 37). 
However we showed that p53 was not increased in 
FAK∆/∆ MEFs (Fig. 2C). Thus, the lack of FAK 
autophosphorylation is likely to inhibit cell 
proliferation by an alternative pathway. 
 The contrast between the phenotype of 
FAK-/- and FAK∆/∆ embryos provides strong 
evidence for autophosphorylation-independent 
functions of FAK in vivo. Such functions have been 
suggested in cultured cells, in addition to the 
aforementioned regulation of p53 expression. For 
example, pharmacological inhibition of FAK did 
not block proliferation of tumor cells and did not 
block their apoptosis in vitro (19). Durotaxis, the 
ability of cells, cultured on a substrate of graded 
stiffness, to move from softer to stiffer regions, was 
abolished in FAK-/- cells and rescued by 
FAKY397F, which did not rescue the migration 
speed (38). Furthermore, abnormal axonal 
branching in hippocampal FAK-/- neurons was 
partially rescued by the expression of FAKY397F 
(7). Although very few bona fide substrates of FAK 
have been characterized in intact cells (1), the 
respective role of FAK catalytic activity and 
scaffolding properties will have to be determined in 
these autophosphorylation-independent functions. 
Auto-phosphorylation-independent function of 
FAK is also supported by the observation that 
although Tyr-397 is highly conserved in most 
metazoans, it is not found in C. elegans (21).  
 In conclusion, the study of FAK∆/∆ mice 
provides important information about the role of 
FAK autophosphorylation on Tyr-397 in vivo. FAK 
autophosphorylation is not required for 
development before E13.5 but becomes necessary 
past that stage. The autophosphorylation of FAK on 
Tyr-397 is not necessary for general cell 
morphology in standard culture conditions or to 
repress p53 and Pyk2 expression. In contrast, it 
plays an important role in focal adhesion turnover, 
lamellipodia formation, cell spreading and 
proliferation. Thus, our results demonstrate that the 
physiological functions of FAK in vivo are achieved 
through both autophosphorylation-independent and 
autophosphorylation-dependent mechanisms and 
that the requirements for these mechanisms vary 
during development. They underline that 
identification of the mechanisms by which FAK 
regulates different cellular functions will be 
important to improve the design of appropriate 
therapeutic tools. 
 
 
 
FAK without autophosphorylation 
 
REFERENCES 
1. Schlaepfer, D. D., Mitra, S. K., and Ilic, D. (2004) Biochim Biophys Acta 1692, 77-102 
2. Chatzizacharias, N. A., Kouraklis, G. P., and Theocharis, S. E. (2008) Histol Histopathol 23, 629-650 
3. Parsons, J. T. (2003) J Cell Sci 116, 1409-1416 
4. Ilic, D., Furuta, Y., Kanazawa, S., Takeda, N., Sobue, K., Nakatsuji, N., Nomura, S., Fujimoto, J., Okada, M., 
and Yamamoto, T. (1995) Nature 377, 539-544 
5. Shen, T. L., Park, A. Y., Alcaraz, A., Peng, X., Jang, I., Koni, P., Flavell, R. A., Gu, H., and Guan, J. L. 
(2005) J Cell Biol 169, 941-952 
6. Beggs, H. E., Schahin-Reed, D., Zang, K., Goebbels, S., Nave, K. A., Gorski, J., Jones, K. R., Sretavan, D., 
and Reichardt, L. F. (2003) Neuron 40, 501-514 
7. Rico, B., Beggs, H. E., Schahin-Reed, D., Kimes, N., Schmidt, A., and Reichardt, L. F. (2004) Nat Neurosci 
7, 1059-1069 
8. Grove, M., Komiyama, N. H., Nave, K. A., Grant, S. G., Sherman, D. L., and Brophy, P. J. (2007) J Cell Biol 
176, 277-282 
9. Nikolopoulos, S. N., and Giancotti, F. G. (2005) Cell Cycle 4, e131-135 
10. Braren, R., Hu, H., Kim, Y. H., Beggs, H. E., Reichardt, L. F., and Wang, R. (2006) J Cell Biol 172, 151-162 
11. Weis, S. M., Lim, S. T., Lutu-Fuga, K. M., Barnes, L. A., Chen, X. L., Gothert, J. R., Shen, T. L., Guan, J. L., 
Schlaepfer, D. D., and Cheresh, D. A. (2008) J Cell Biol 181, 43-50 
12. Vadali, K., Cai, X., and Schaller, M. D. (2007) IUBMB Life 59, 709-716 
13. Peng, X., Wu, X., Druso, J. E., Wei, H., Park, A. Y., Kraus, M. S., Alcaraz, A., Chen, J., Chien, S., Cerione, 
R. A., and Guan, J. L. (2008) Proc Natl Acad Sci U S A 105, 6638-6643 
14. Hakim, Z. S., Dimichele, L. A., Doherty, J. T., Homeister, J. W., Beggs, H. E., Reichardt, L. F., Schwartz, R. 
J., Brackhan, J., Smithies, O., Mack, C. P., and Taylor, J. M. (2007) Mol Cell Biol 27, 5352-5364 
15. Vallejo-Illarramendi, A., Zang, K., and Reichardt, L. F. (2009) J Clin Invest 119, 2218-2230 
16. Mitra, S. K., Hanson, D. A., and Schlaepfer, D. D. (2005) Nat Rev Mol Cell Biol 6, 56-68 
17. Hanks, S. K., Ryzhova, L., Shin, N. Y., and Brabek, J. (2003) Front Biosci 8, d982-996 
18. Playford, M. P., and Schaller, M. D. (2004) Oncogene 23, 7928-7946 
19. Slack-Davis, J. K., Martin, K. H., Tilghman, R. W., Iwanicki, M., Ung, E. J., Autry, C., Luzzio, M. J., 
Cooper, B., Kath, J. C., Roberts, W. G., and Parsons, J. T. (2007) J Biol Chem 282, 14845-14852 
20. Lim, S. T., Chen, X. L., Lim, Y., Hanson, D. A., Vo, T. T., Howerton, K., Larocque, N., Fisher, S. J., 
Schlaepfer, D. D., and Ilic, D. (2008) Mol Cell 29, 9-22 
21. Corsi, J. M., Rouer, E., Girault, J. A., and Enslen, H. (2006) BMC Genomics 7, 198 
22. Burgaya, F., Toutant, M., Studler, J. M., Costa, A., Le Bert, M., Gelman, M., and Girault, J. A. (1997) J Biol 
Chem 272, 28720-28725 
23. Toutant, M., Costa, A., Studler, J. M., Kadare, G., Carnaud, M., and Girault, J. A. (2002) Mol Cell Biol 22, 
7731-7743 
24. Tournier, C., Hess, P., Yang, D. D., Xu, J., Turner, T. K., Nimnual, A., Bar-Sagi, D., Jones, S. N., Flavell, R. 
A., and Davis, R. J. (2000) Science 288, 870-874 
25. Sieg, D. J., Ilic, D., Jones, K. C., Damsky, C. H., Hunter, T., and Schlaepfer, D. D. (1998) Embo J 17, 5933-
5947 
26. Furuta, Y., Ilic, D., Kanazawa, S., Takeda, N., Yamamoto, T., and Aizawa, S. (1995) Oncogene 11, 1989-
1995 
27. Weed, S. A., and Parsons, J. T. (2001) Oncogene 20, 6418-6434 
28. Lim, Y., Lim, S. T., Tomar, A., Gardel, M., Bernard-Trifilo, J. A., Chen, X. L., Uryu, S. A., Canete-Soler, R., 
Zhai, J., Lin, H., Schlaepfer, W. W., Nalbant, P., Bokoch, G., Ilic, D., Waterman-Storer, C., and Schlaepfer, 
D. D. (2008) J Cell Biol 180, 187-203 
29. Owen, J. D., Ruest, P. J., Fry, D. W., and Hanks, S. K. (1999) Mol Cell Biol 19, 4806-4818 
30. Katz, B. Z., Romer, L., Miyamoto, S., Volberg, T., Matsumoto, K., Cukierman, E., Geiger, B., and Yamada, 
K. M. (2003) J Biol Chem 278, 29115-29120 
31. Ruest, P. J., Shin, N. Y., Polte, T. R., Zhang, X., and Hanks, S. K. (2001) Mol Cell Biol 21, 7641-7652 
32. Serrels, B., Serrels, A., Brunton, V. G., Holt, M., McLean, G. W., Gray, C. H., Jones, G. E., and Frame, M. 
C. (2007) Nat Cell Biol 9, 1046-1056 
33. Tilghman, R. W., Slack-Davis, J. K., Sergina, N., Martin, K. H., Iwanicki, M., Hershey, E. D., Beggs, H. E., 
Reichardt, L. F., and Parsons, J. T. (2005) J Cell Sci 118, 2613-2623 
34. Cox, B. D., Natarajan, M., Stettner, M. R., and Gladson, C. L. (2006) J Cell Biochem 99, 35-52 
35. Schober, M., Raghavan, S., Nikolova, M., Polak, L., Pasolli, H. A., Beggs, H. E., Reichardt, L. F., and Fuchs, 
E. (2007) J Cell Biol 176, 667-680 
FAK without autophosphorylation 
36. Cance, W. G., and Golubovskaya, V. M. (2008) Sci Signal 1, pe22 
37. Golubovskaya, V. M., Finch, R., and Cance, W. G. (2005) J Biol Chem 280, 25008-25021 
38. Wang, H. B., Dembo, M., Hanks, S. K., and Wang, Y. (2001) Proc Natl Acad Sci U S A 98, 11295-11300 
 
 
ACKNOWLEDGEMENTS  
The authors thank D. Ilic (StemLifeline Inc) for providing FAK-/- MEF, S. Marullo and C. Boularan 
(Institut Cochin, Inserm U567) for providing the Luc-p53 plasmid, I. Bachy (Karolinska Institutet, 
Stockholm Sweden), M. Holzenberger (Inserm UMR-S893), P. Gaspar, D. Hervé, J. Bertran-Gonzalez, R-
M. Mège (Inserm UMR-S U839) and J. Chelly (Institut Cochin, Inserm UMR-S567), for helpful 
discussions as well as members of the “Plateforme de Recombinaison Homologue” (Institut Cochin, 
Inserm UMR-S567, CNRS UMR8104), of the Cell Imaging and Animal Facilities and S. Clain (Inserm 
UMR-S839) for their help. This work was supported by Inserm and by grants from the Association pour la 
Recherche sur le Cancer to H.E. (3746) and to J.A.G. (3138), and from Agence Nationale de la Recherche 
(ANR-05-2_42589) to J.A.G. 
 
 
FAK without autophosphorylation 
FIGURE LEGENDS 
 
Figure 1: Late defects and lethality in FAK∆/∆  embryos. (A) Schematic FAK and FAK∆ structure, 
showing the N-terminal FERM domain, the kinase domain and the C-terminal focal adhesion targeting 
(FAT) domain, as well as proline-rich sequences (PR1-3). FAK∆ lacks 19 amino acids in the FERM-kinase 
linker, including Tyr-397. (B) Comparison of the in utero survival curves of FAK-null and 
FAK∆/∆ embryos (red inverted triangles). The data concerning FAK-null embryos are from (26) (FAK-/-, 
green squares) and (5) (CFKO, magenta triangles). (C) Appearance of FAK+/+ and FAK∆/∆ embryos at 
E13.5 and E15.5 (arrows: hemorrhages; arrowheads: edemas). Gross morphology defects of E14.5 FAK+/+ 
and FAK∆/∆ lungs, heart, and liver (scale bars, 1 mm). E14.5 (upper panel) and E15.5 (lower panel) anterior 
(left) and posterior (right) footplates (scale bars, 1 mm). (D) FAK∆/∆ embryos show delayed artery 
formation and vascular remodeling defects. Whole-mount triple immunofluorescence confocal microscopy 
using antibodies to SMA (Smooth Muscle Actin, green), PECAM1 (red) and neurons (TUJ1) (blue) on 
skin from E14,5 embryos. Confocal microscopy images were acquired using 10X magnification. 
 
Figure 2:  Expression of FAK-associated proteins in tissue from FAK∆/∆ embryos and mutant MEFs.  
(A) Immunoblotting of phospho-Tyr-397 (pY397), FAK, vinculin (Vinc), p130-Cas (Cas), paxillin (Pax), 
cortactin (Cort), Src and Fyn in  liver lysates from FAK+/+, FAK+/∆ and FAK∆/∆  E14.5 littermate embryos. 
(B) Immunoblotting of the same proteins as in (A), Pyk2, and GAPDH in MEFs derived from E12.5 
FAK+/+ and FAK∆/∆ littermate embryos. (C) Immunoblotting for p53 in MEFs as in (B), Lysates from COS7 
cells expressing a fusion luciferase-p53 protein was used as a control for p53 immunoreactivity.  
 
Figure 3: Alteration of the phosphorylation response to integrin engagement in FAK∆/∆  MEFs.  MEFs 
were plated on polylysine (Pl) or fibronectin (Fn) for 30 min before lysis and immunoblottings for 
phospho-Tyr-397, 576, 577, 925 and total FAK (A) and quantified (B). Immunoblotting of tyrosine 
phosphorylated (p, upper panels) and total levels (middle panels) of Cas (C), Pax (D), and Cort (E) in 
MEFs plated as in (A). These experiments have been repeated with independent FAK+/+ or FAK∆/∆  (n=3 for 
each genotype) MEFs populations established from different littermate embryos. Quantified data (means ± 
SEM n= 3) were analyzed using two-way ANOVA. Bonferroni post-test: * p < 0.05, ** p < 0.01, *** p < 
0.001. 
 
Figure 4: Delayed spreading and abnormal lamellipodia in FAK∆/∆ fibroblasts and endothelial cells. 
FAK+/+ and FAK∆/∆ MEFs or endothelial cells (EC) were plated on polylysine (Pl) or fibronectin (Fn) for 
0.5-20 h as indicated. Cells were stained for actin with rhodamin-conjugated phalloidin (A-D, F) and/or 
antibodies recognizing FAK (A, D, E), cortactin (B, F), vinculin (C, F) and revealed with FITC-conjugated 
secondary antibody. EC cells (E, F) were identified by CD31 immunostaining. Lamellipodia were well 
developed in wild type (arrows) but not mutant cells (A-B and D-F), which displayed narrow cortactin-
positive protrusions (B, F). Focal adhesions were more numerous and larger in FAK∆/∆ than wild type cells 
(C, D, E, F). Scale bars: 20 µm. 
 
Figure 5: Proliferation is slowed in FAK∆/∆ MEFs. (A) Independent MEFs populations (n=3-4 for each 
genotype) established from littermate embryos were plated separately in triplicate (7500 cells/well) and 
grown in 10% serum, for the indicated number of days. Cell number was evaluated by crystal violet 
staining and the day after plating was considered as D=0. (B) FAK+/+ and FAK∆/∆ MEFs populations were 
grown in the indicated serum concentrations and counted by crystal violet staining at D=0 or after 7 days in 
culture (D=7). Data (means ± SEM n= 3-4) were analyzed using two-way ANOVA. Bonferroni post-test: 
** p < 0.01, *** p < 0.001. 
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Table 1: Genotype of embryos obtained from crosses between FAK+/∆ mice. The total number of embryos 
(alive or dead) of each genotype obtained from crosses between (FAK+/∆) mice is indicated at various 
embryonic ages and birth. The number of dead embryos is indicated between parentheses. 
Embryonic day 11.5 12.5 13.5 14.5 15.5 16.5 18.5 Born 
+/+ 20 (1) 11(1) 22 30 18 (1) 16 10 213 
+/∆ 46 (2) 22 78 84 (5) 51 (1) 39 (1) 17 416 
∆/∆ 26 (7) 10 33 (11) 42 (17) 11 (5) 7 (4) 1 (1) 3 
Number of litters 12 5 18 21 11 6 5 94 
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Suppl. Fig. 1: Generation and analysis of FAKΔ/Δ mutant mice. (A) Structure and restriction maps of 
the wild-type mouse FAK (Ptk2) gene, targeting vector and the obtained allele. Constitutive and 
alternative exons are figured by dark or white vertical boxes respectively, with their number (Corsi et 
al., 2006) indicated below. The insertion of a pgk-hygromycin (HYGRO)-resistance cassette flanked 
with FRT sites (ovals) allowed the deletion of alternative exons 13 and 14, and the positive selection 
of the homologous recombination event. Note that deletion of exons 13 and 14 is expected to have no 
consequence during early embryogenesis since they are not detected in mRNA during the first part of 
embryonic development [Corsi, 2006 #26]. The LoxP sequences (triangles) flanking the alternative 
exon 16 were placed for possible conditional deletion of this exon by the Cre recombinase. The 
position of the 5’ and 3’ probes used for Southern blots are indicated. Arrows represent the position of 
the primers (P1, P2, P3) used for genotyping by PCR. Abbreviations for the restriction sites are: P: 
PstI, M: MstII, B: BamH1, A: BstI, X: XmnI, G: BglII, S: SfiI. (B) Southern blot analyses of the ES 
cells clones. ES clones were electroporated and cultured at the Homologous recombination-transgenic 
core facility of the Cochin Institute. Genomic DNA was digested with PstI (5’) or XmnI (3’). The 
wild-type allele produced an 8.4 kb fragment with the 5' probe and a 12.5 kb with the 3' probe, while 
the targeted allele produced a 6.5 kb fragment with the 5' probe and a 7.5 kb fragment with the 3' 
probe. (C) Immunoblot analyses of FAK and FAKΔ expression in wild-type (+/+) and heterozygous 
(+/Δ) F1 adult mice. The results obtained from two mice of each genotype are shown. Immunoblotting 
of proteins extracted from liver or other organs (data not shown) was carried out with antibodies 
recognizing specifically the N-terminal (top panel, blot N-ter) or the C-terminal (bottom panel, blot C-
ter) domain of FAK.  
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Suppl. Fig. 2: Transphosphorylation of FAK Tyr-397 in COS7 cells. To determine whether FAK∆ 
was active in cells we used the ability of FAK to undergo trans autophosphorylation in intact cells (ref 
Toutant et al, MCB 2002). COS7 cells were transfected with FAK, FAK∆ and FAKK454R, the 
kinase-dead form of FAK, alone or with a combination of FAK∆ and FAKK454R. Immunoblotting of 
cell lysates was carried out with antibodies recognizing specifically FAK phosphorylated on Tyr-397 
or independently of its phosphorylation state. As expected wild-type FAK was phosphorylated on Tyr-
397 (lane 5) whereas neither FAK-K454R (lane 2) nor FAK∆ (lane 3) transfected alone were 
phosphorylated compared to control cells (lane 1). In contrast when these two mutated forms of FAK 
were transfected together, phosphorylation of FAK-K454R on Tyr-397 was observed (lane 4). These 
results demonstrate that FAK∆ is an active kinase. Bar graphs represent the level of Tyr-397 
autophosphorylation in each condition, expressed as a percentage +/- sem of autophosphorylation of 
transfected normal FAK (lane 5), set to 100% (n=10). 
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Suppl. Fig. 3: (A) FAKΔ/Δ  embryos appear normal at E.11.5. (a-d) Gross morphology of FAK+/+  (a, b) 
and FAKΔ/Δ  (c, d) E11.5 embryos in the yolk sac (a, c) or outside of the yolk sac (b, d). (e-l) whole 
mount PECAM-1 immunohistochemistry of E11.5 embryos. Pictures of the whole embryos (e, g) and 
magnified pictures of the top of the head (f, h), the somites (i, k) and the forelimb (j, l) are shown. No 
vasculature abnormality was detected at that age. Embryos were examined and photographed on a 
dissecting microscope (model DMIL; Leica) with a progressive 3CCD camera (Cool Snap 
Photometrics, Roper Scientific) and QED capture version 2.0.33 (Media Cybernetics) at RT. (B) 
Vascular abnormalities in the yolk sac of FAKΔ/Δ embryos after E13.5. Pictures of FAK+/+ and FAKΔ/Δ 
embryos in their yolk sacs at E13.5, E14.5, and E15.5 are shown. Scale bars in A: a,e, 2mm; f, 1mm; 
in B: 2mm. 
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Suppl. Fig. 4: Rare FAK∆/∆  mice survive to adulthood. (A) Heterozygous (FAK+/∆) and homozygous 
(FAK∆/∆) adult mice at 12 months. Three viable adult homozygous mice were obtained among a total 
of 632 genotyped mice from 94 litters. These mice crossed with wild type mice were fertile. (B) PCR 
analysis confirmed the genotype of adult mutant mice. Primers used were: P1: 5’-
GTAGAAGTACTCGCCGATAG-3’, P2: 5’-AATCACTCCAGTATAGTGCC-3’ and P3: 5’-
CCTTAGATGTGGGTCTTAAT-3’ and their localization on the fak gene is shown in Supplemental 
figure 1A. The combination of the P1 and P3 primers selectively amplified a 1.3 kb fragment from the 
FAKΔ allele. The combination of the P2 and P3 primers amplified a 0.7 kb fragment from the FAKΔ 
allele and a 1 kb fragment from the wild type allele respectively. Fragments were separated on 0.8% 
agarose gels. The three products are seen in a heterozygous FAK+/∆ mouse, whereas the band 
corresponding to the wild type allele is absent in an adult homozygous mutant mouse (FAK∆/∆). 
 
 
